An April 18 Business section brief incorrectly stated the revenue generated by Computer Systems Technology, a company acquired by Science Applications International Corp. SAIC said the firm had more than $90 million in revenue last year. (Published 4/19/03)

* Science Applications International Corp., a San Diego-based information technology and engineering firm, said it acquired Computer Systems Technology, a Huntsville, Ala., information technology company. Financial terms were not disclosed. Computer Systems Technology will remain in Huntsville and will become part of SAIC's technology applications unit, which is based in McLean. SAIC said the 14-year-old private company has a number of federal government clients, including the Defense Department, the Treasury Department and the General Services Administration. SAIC also said Computer Systems Technology had more than $900 million in revenue last year. The unit will be called the Computer Systems Technology Group of SAIC. The acquisition was not previously announced, an SAIC spokesman said.

* Veridian, an Arlington government contractor, said it was awarded a contract potentially worth $19.7 million with the National Reconnaissance Office. Under the contract, which includes a base year plus four optional extensions, Veridian will provide administrative and technical support.

* Martek Biosciences, a Columbia biotech company, said the 2.5 million shares of common stock it expects to issue next week will be priced at $30.25 per share. The firm expects net proceeds of $71 million from the sale.

* DynPort Vaccine of Frederick said that patients responded positively to its new smallpox vaccine in a preliminary study. The privately held company, a joint venture between Computer Sciences Corp. and Porton International, said 150 patients who received an undiluted dose of the vaccine, called CCSV, exhibited signs of immunization. Of those, 100 had never been vaccinated against smallpox before. Even when diluted up to 50 times, the vaccine produced positive results in all but one out of 100 patients. The early-stage study also indicates patients vaccinated with CCSV were slightly less likely to experience common side effects -- including fatigue, rash and higher temperature -- than those given Dryvax, the 30-year-old smallpox vaccine now being stockpiled in the event of a bioterror attack.

Compiled from reports by Washington Post staff writers, and Dow Jones News Service